Clinical Trial

Investigating Dupilumab's Effect in Asthma by Genotype

Study acronym: IDEA
Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The Goal of this study is to investigate if individuals ages 12 years and older, carrying the IL-4RαR576 gene variant, will have a greater response to therapy acting directly on the anti-IL-4R. This will be conducted by examining the effect of a 48 week therapy with dupilumab on the rate of asthma exacerbations.
Protocol Amendment History 26 amendments
This ClinicalTrials.gov record has been amended 26 times since 2018-10-01; most recent amendment 2026-02-20.
Status change: Recruiting → Active, Not Recruiting 2026-02-20
Status change: Not Yet Recruiting → Recruiting 2021-11-03
Trial Details
NCT Number NCT03694158
Lead Sponsor Boston Children's Hospital
Collaborators: National Institute of Allergy and Infectious Diseases (NIAID), Regeneron Pharmaceuticals, HealthBeacon Plc, Merck Sharp & Dohme LLC, Sanofi
Conditions Asthma
Enrollment 150 participants
Start Date 2021-09-08
Primary Completion 2027-01 (estimated)
Study Completion 2027-03 (estimated)
Updated on ClinicalTrials.gov 2026-02-23